INSMED INC Purchase Obligation
INSMED INC (INSM) had Purchase Obligation of $63.00 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2026-02-19
- 2025-12-31: Purchase Obligation $63.00M.
- 2024-12-31: Purchase Obligation $66.60M.
- 2023-12-31: Purchase Obligation $92.70M.
- 2022-12-31: Purchase Obligation $75.10M.
| Period end | Purchase Obligation |
|---|---|
| 2025-12-31 | $63.00M 10-K · filed 2026-02-19 |
| 2024-12-31 | $66.60M 10-K · filed 2025-02-20 |
| 2023-12-31 | $92.70M 10-K · filed 2024-02-22 |
| 2022-12-31 | $75.10M 10-K · filed 2023-02-23 |
| 2021-12-31 | $78.20M 10-K · filed 2022-02-17 |
| 2020-12-31 | $83.10M 10-K · filed 2021-02-25 |
| 2019-12-31 | $82.00M 10-K · filed 2020-02-25 |
| 2018-12-31 | $86.40M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |